{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:39:25Z","timestamp":1769881165909,"version":"3.49.0"},"reference-count":59,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder characterised by the progressive demyelination of peripheral nerves, resulting in motor and sensory deficits. While much research has focused on clinical and electrophysiological aspects of CIDP, there is an emerging interest in exploring its impact on the visual system through visual evoked potentials (VEPs). This comprehensive review synthesises existing literature on VEP findings in CIDP patients, shedding light on their potential diagnostic and prognostic value. The review thoroughly examines studies spanning the last two decades, exploring VEP abnormalities in CIDP patients. Notably, VEP studies have consistently revealed prolonged latencies and reduced amplitudes in CIDP patients compared to healthy controls. These alterations in VEP parameters suggest that the demyelinating process extends beyond the peripheral nervous system to affect the central nervous system, particularly the optic nerve and its connections. The correlation between VEP abnormalities and clinical manifestations of CIDP, such as visual impairment and sensory deficits, underscores the clinical relevance of VEP assessment in CIDP management. Furthermore, this review addresses the potential utility of VEPs in aiding CIDP diagnosis and monitoring disease progression. VEP abnormalities may serve as valuable biomarkers for disease activity, helping clinicians make timely therapeutic decisions. Moreover, this review discusses the limitations and challenges associated with VEP assessment in CIDP, including variability in recording techniques and the need for standardised protocols. In conclusion, this review highlights the evolving role of VEPs as a non-invasive tool in CIDP evaluation. The consistent VEP abnormalities observed in CIDP patients suggest the involvement of the central nervous system in this demyelinating disorder. As our understanding of CIDP and its pathophysiology continues to evolve, further research in this area may lead to improved diagnostic accuracy and monitoring strategies, ultimately enhancing the clinical management of CIDP patients.<\/jats:p>","DOI":"10.3390\/medicina59122160","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T04:14:42Z","timestamp":1702440882000},"page":"2160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronic Inflammatory Demyelinating Polyneuropathy and Evaluation of the Visual Evoked Potentials: A Review of the Literature"],"prefix":"10.3390","volume":"59","author":[{"given":"Periklis","family":"Tsoumanis","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Kitsouli","sequence":"additional","affiliation":[{"name":"Anatomy-Histology-Embryology, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-9485","authenticated-orcid":false,"given":"Christos","family":"Stefanou","sequence":"additional","affiliation":[{"name":"Department of Surgery, General Hospital of Filiates, 46300 Filiates, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-5326","authenticated-orcid":false,"given":"Georgios","family":"Papathanakos","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanos","family":"Stefanou","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Henry Dunant Hospital Center, 11526 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Tepelenis","sequence":"additional","affiliation":[{"name":"Department of Surgery, General Hospital of Ioannina G. Hatzikosta, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hercules","family":"Zikidis","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afroditi","family":"Tsoumani","sequence":"additional","affiliation":[{"name":"Department of Neurology, G. Hatzikosta, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevas","family":"Zafeiropoulos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Kitsoulis","sequence":"additional","affiliation":[{"name":"Anatomy-Histology-Embryology, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Kanavaros","sequence":"additional","affiliation":[{"name":"Anatomy-Histology-Embryology, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.clinph.2019.04.575","article-title":"P39-S Multimodal evoked potentials in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)","volume":"130","author":"Dziadkowiak","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: Update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00415-020-09916-y","article-title":"Environmental factors and physical activity impact disability and quality of life in CIDP","volume":"267","author":"Doneddu","year":"2020","journal-title":"J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force\u2014Second revision","volume":"28","author":"Hadden","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0960-8966(00)00119-X","article-title":"Childhood chronic inflammatory demyelinating polyneuropathy: Clinical course and long-term outcome","volume":"10","author":"Ryan","year":"2000","journal-title":"Neuromuscul. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/jnnp.53.9.794","article-title":"Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy","volume":"53","author":"Hawke","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_7","first-page":"S371","article-title":"Chronic inflammatory demyelinating polyneuropathy: Considerations for diagnosis, management, and population health","volume":"24","author":"Ryan","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nmd.2018.06.001","article-title":"Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Silwal","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2010.03312.x","article-title":"Non-anti- MAG DADS neuropathy as a variant of CIDP: Clinical, electrophysiological, laboratory features and response to treatment in 10 cases","volume":"18","author":"Larue","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_11","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin- associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.54.1.26","article-title":"Multifocal inflammatory demyelinating neuropathy: A distinct clinical entity?","volume":"54","author":"Franssen","year":"2000","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/jnnp-2013-306105","article-title":"Chronic inflammatory demy-elinating polyradiculoneuropathy: Search for factors associated with treatment dependence or successful withdrawal","volume":"85","author":"Rabin","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1097-4598(200002)23:2<283::AID-MUS23>3.0.CO;2-Q","article-title":"Chronic demyelinating hypertrophic brachial plexus neuropathy","volume":"23","author":"Thonnard","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s004150170093","article-title":"Pure motor chronic inflammatory demyelinating polyneuropathy","volume":"248","author":"Sabatelli","year":"2001","journal-title":"J. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014First revision. J. Peripher. Nerv. Syst., 15, 295\u2013301.","DOI":"10.1111\/j.1529-8027.2010.00290.x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jns.12380","article-title":"Motor chronic inflamma-tory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treat-ment","volume":"25","author":"Pegat","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Eftimov, F., Liesdek, M.H., Verhamme, C., van Schaik, I.N., and PREDICT Study Group (2014). Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol., 14.","DOI":"10.1186\/1471-2377-14-72"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.23821","article-title":"Sensory chronic inflammatory demyelinating polyneuropathy: An under-recognized entity?","volume":"48","author":"Ayrignac","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1212\/01.wnl.0000188879.19900.b7","article-title":"Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP","volume":"65","author":"Sommer","year":"2005","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/mus.26028","article-title":"Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review","volume":"57","author":"Rajabally","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/ene.14742","article-title":"Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_24","unstructured":"Willison, H.J., O\u2019Leary, C.P., and Veitch, J. (2017). Peripheral Neuropathy, Academic Press."},{"key":"ref_25","first-page":"134","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"89","author":"Querol","year":"2017","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"key":"ref_27","first-page":"134","article-title":"Epidemiology of chronic inflammatory demyelinating polyneuropathy in the province of Li\u00e8ge, Belgium","volume":"42","author":"Nicholson","year":"2014","journal-title":"Neuroepidemiology"},{"key":"ref_28","first-page":"1892","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: A clinical and electrophysiological study of 92 cases","volume":"132","author":"McCombe","year":"2009","journal-title":"Brain"},{"key":"ref_29","first-page":"249","article-title":"Diagnosis and treatment in inflammatory neuropathies","volume":"80","author":"Lunn","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","first-page":"409","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"Koski","year":"2004","journal-title":"Semin. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mus.24088","article-title":"Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy","volume":"50","author":"Breiner","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","article-title":"Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: A multicentre, open-label, 52-week phase III trial","volume":"88","author":"Kuwabara","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/brain\/awab116","article-title":"Elucidating autoimmune nodopathies and the CIDP spectrum","volume":"144","author":"Hadden","year":"2021","journal-title":"Brain"},{"key":"ref_35","first-page":"e1465","article-title":"MR neurography of chronic inflammatory demyelinating polyneuropathy","volume":"94","author":"Kroner","year":"2020","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.25368","article-title":"MR neurography for the evaluation of CIDP","volume":"55","author":"Ishikawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00415-017-8543-7","article-title":"Large coverage MR neurography in CIDP: Diagnostic accuracy and electrophysiological correlation","volume":"264","author":"Kronlage","year":"2017","journal-title":"J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jns.2015.11.048","article-title":"Contribution of plexus MRI in the diagnosis of atypical chronic inflammatory demyelinat-ing polyneuropathies","volume":"360","author":"Lozeron","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/mus.26010","article-title":"Neurofascin-155 IGG4 neuropathy: Pathophysiological Insights, the spectrum of clinical severity and response to treatment","volume":"57","author":"Garg","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_40","unstructured":"Gorson, K.C., Ropper, A.H., and Adelman, L.S. (2005). Immune-Mediated Neuromuscular Diseases, Humana Press."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s10072-020-04351-3","article-title":"Abnormality of multimodal evoked potentials in Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)","volume":"41","author":"Dziadkowiak","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/acn3.593","article-title":"Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy","volume":"5","author":"Graf","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2155-9562.1000105","article-title":"CNS involvement in chronic inflammatory demyelinating polyneuropathy: A visual evoked potential study","volume":"1","author":"Takeda","year":"2010","journal-title":"J. Neurol. Neurophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7150\/ijms.38363","article-title":"Progress in Hematopoietic Stem Cell Transplantation for CIDP","volume":"17","author":"Qin","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-0039-1693008","article-title":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","volume":"39","author":"Shije","year":"2019","journal-title":"Semin. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000008742","article-title":"The thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"ref_47","first-page":"CD010369","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.25652","article-title":"Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy","volume":"57","author":"Markvardsen","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Bril","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40263-019-00655-x","article-title":"Immune Globulin Subcutaneous (Human) 20%(Hizentra\u00ae): A Review in Chronic Inflammatory Demyelinating Polyneuropathy","volume":"33","author":"Lamb","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10072-020-04983-5","article-title":"Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: A chance to verify the need for chronic maintenance therapy","volume":"42","author":"Romozzi","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","article-title":"Corticosteroids in Chronic Inflammatory Demyelinating Polyneuropathy","volume":"265","author":"Peric","year":"2018","journal-title":"J. Neurol."},{"key":"ref_54","first-page":"3","article-title":"Pulsed intravenous corticosteroids in chronic inflammatory demyelinating polyneuropathy: Why not?","volume":"6","author":"Orsucci","year":"2019","journal-title":"Neuroimmunol. Neuroinflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CND.0000000000000179","article-title":"Pediatric CIDP: Clinical features and response to treatment","volume":"19","author":"Harada","year":"2017","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1097\/01.AOG.0000514659.74781.24","article-title":"An Incidence of Chronic Inflammatory Demyelinating Polyneuropathy in Pregnancy [28L]","volume":"129","author":"Manley","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s00415-017-8599-4","article-title":"Severe refractory CIDP: A case series of 10 patients treated with bortezomib","volume":"264","author":"Pitarokoili","year":"2017","journal-title":"J. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jns.12287","article-title":"Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases","volume":"23","author":"Roux","year":"2018","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(17)30471-4","article-title":"IgG4-related disease of the central and peripheral nervous systems","volume":"17","author":"AbdelRazek","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:37:55Z","timestamp":1760132275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["medicina59122160"],"URL":"https:\/\/doi.org\/10.3390\/medicina59122160","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}